Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Votubia 5mg dispersible tablets
0801050AXBCAFAI
|
Votubia | Everolimus | Malignant Disease and Immunosuppression | No data available |
|
Votubia 5mg tablets
0801050AXBCAAAA
|
Votubia | Everolimus | Malignant Disease and Immunosuppression | No data available |
|
Xeloda 150mg tablets
0801030V0BBABAB
|
Xeloda | Capecitabine | Malignant Disease and Immunosuppression | No data available |
|
Xeloda 500mg tablets
0801030V0BBAAAA
|
Xeloda | Capecitabine | Malignant Disease and Immunosuppression | No data available |
|
Xospata 40mg tablets
0801030AGBBAAAA
|
Xospata | Gilteritinib | Malignant Disease and Immunosuppression | No data available |
|
Xtandi 40mg capsules
0803042U0BBAAAA
|
Xtandi | Enzalutamide | Malignant Disease and Immunosuppression | No data available |
|
Xtandi 40mg tablets
0803042U0BBABAB
|
Xtandi | Enzalutamide | Malignant Disease and Immunosuppression | No data available |
|
Yervoy 200mg/40ml concentrate for inf vials
0801050BCBBABAB
|
Yervoy | Ipilimumab | Malignant Disease and Immunosuppression | No data available |
|
Yervoy 50mg/10ml concentrate for solution for infusion vials
0801050BCBBAAAA
|
Yervoy | Ipilimumab | Malignant Disease and Immunosuppression | No data available |
|
Yondelis 0.25mg pdr for concentrate for inf vials
0801050AVBBAAAA
|
Yondelis | Trabectedin | Malignant Disease and Immunosuppression | No data available |
|
Yondelis 1mg pdr for concentrate for inf vials
0801050AVBBABAB
|
Yondelis | Trabectedin | Malignant Disease and Immunosuppression | No data available |
|
Zanubrutinib 80mg capsules
0801050CSAAAAAA
|
Zanubrutinib | Zanubrutinib | Malignant Disease and Immunosuppression | No data available |
|
Zavedos 10mg capsules
0801020P0BBACAD
|
Zavedos | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Zavedos 10mg powder for solution for injection vials
0801020P0BBABAB
|
Zavedos | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Zavedos 10mg/10ml solution for injection vials
0801020P0BBAGAF
|
Zavedos | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Zavedos 25mg capsules
0801020P0BBADAE
|
Zavedos | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Zavedos 5mg capsules
0801020P0BBAEAC
|
Zavedos | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Zavedos 5mg powder for solution for injection vials
0801020P0BBAAAA
|
Zavedos | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Zavedos 5mg/5ml solution for injection vials
0801020P0BBAFAG
|
Zavedos | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Zejula 100mg capsules
0801050CJBBAAAA
|
Zejula | Niraparib | Malignant Disease and Immunosuppression | No data available |
|
Zelboraf 240mg tablets
0801050BDBBAAAA
|
Zelboraf | Vemurafenib | Malignant Disease and Immunosuppression | No data available |
|
Zenapax 25mg/5ml solution for infusion vials
0802020V0BBAAAA
|
Zenapax | Daclizumab | Malignant Disease and Immunosuppression | No data available |
|
Zeposia 0.23mg/0.46mg capsules treatment initiation pack
0802040BFBBABAB
|
Zeposia | Ozanimod | Malignant Disease and Immunosuppression | No data available |
|
Zeposia 0.92mg capsules
0802040BFBBAAAA
|
Zeposia | Ozanimod | Malignant Disease and Immunosuppression | No data available |
|
Zercepac 150mg pdr for concentrate for inf vials
0801050ADBHAAAA
|
Zercepac | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.